Anti-Obesity Drugs Market Size to Reach USD 70.31 Billion by 2035 | SNS Insider

The U.S. anti-obesity drugs market is projected to rise from $2.27B in 2025 to $19.64B by 2035, while Europe is expected to grow from $1.88B to $16.94B. Growth is attributed to increasing GLP-1 therapy adoption, wider reimbursement coverage, and continued treatment innovation—supporting a constructive demand outlook for the sector.

Analysis

The equity opportunity is less about the market size headline and more about who captures chronic-use economics. Eli Lilly and Novo Nordisk are the clear winners, but the second-order upside is concentrated in names with manufacturing scale, payer access, and adherence tooling; pure-play GLP-1 demand by itself does not guarantee margin expansion if rebates, shortages, or compounding pressure persist.

The biggest losers are not just direct obesity-treatment substitutes, but high-calorie consumption proxies: packaged snacks, sugary beverages, and some quick-service food baskets. The effect will likely show up first as mix shift and weaker basket growth rather than a dramatic unit collapse, which means the market may overstate how quickly consumer staples get hit. Pharmacies and PBMs can benefit from traffic and script growth, but if coverage broadens too quickly the cost burden shifts back to insurers, creating a margin headwind for managed care.

Catalysts sit on a 1-3 month and 6-18 month clock. Near term, watch payer formulary updates, earnings guidance on net price versus volume, and any commentary on manufacturing bottlenecks; those are the real falsifiers. Over 6-18 months, the key question is whether oral GLP-1s and next-gen agents extend duration of therapy enough to justify the implied TAM, or whether discontinuation and price compression cap the revenue pool.

Consensus may be underestimating how much of the value accrues to duration and distribution rather than to the broad obesity category itself. The move is probably overdone to short all food/consumer names, but underdone in that branded pharma still has room if reimbursement normalizes and supply catches up.

Key Decisions for Investors

• Long LLY / short XLP on a 3-6 month horizon: expresses GLP-1 adoption while hedging broad consumer beta; attractive if volume shift in food accelerates but valuation risk remains contained.
• Add NVO only on pullbacks, not breakouts: use a 6-12 month call spread if payer coverage continues to broaden; thesis breaks if U.S. pricing or supply commentary deteriorates.
• Watchlist short for consumer staples with high sugar/snack exposure (K, HSY, GIS, CAG) into the next two earnings cycles; confirm with soft volume/mix commentary before taking size.
• Avoid chasing managed care long exposure purely on coverage expansion; if obesity benefits get broadly reimbursed, UNH/CVS face utilization cost risk before they see enough offsetting volume.
• Set a catalyst alert on insurer and pharma guidance over the next quarter: if net pricing weakens or discontinuation rates stay elevated, cut exposure to the obesity complex and rotate back into defensive consumer names.